key: cord-0751821-epzpua9t
authors: Pickering, S.; Batra, R.; Snell, L. B.; Merrick, B.; Nebbia, G.; Douthwaite, S.; Patel, A.; Ik, M. T.; Patel, B.; Charalampous, T.; Alcolea-Medina, A.; Lista, M. J.; Cliff, P. R.; Cunningham, E.; Mullen, J.; Doores, K. J.; Edgeworth, J. D.; Malim, M. H.; Neil, S. J.; Galao, R. P.
title: Comparative performance of SARS-CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity detection of infectious virus in clinical specimens
date: 2021-03-02
journal: nan
DOI: 10.1101/2021.02.27.21252427
sha: 4dd16c34e61c0affbd3518f0d6525edab07dda78
doc_id: 751821
cord_uid: epzpua9t

Background: Rapid antigen lateral flow devices (LFDs) are set to become a cornerstone of SARS-CoV-2 mass community testing. However, their reduced sensitivity compared to PCR has raised questions of how well they identify infectious cases. Understanding their capabilities and limitations is therefore essential for successful implementation. To address this, we evaluated six commercial LFDs on the same collection of clinical samples and assessed their correlation with infectious virus culture and cycle threshold (Ct) values. Methods: A head-to-head comparison of specificities and sensitivities was performed on six commercial rapid antigen tests using combined nasal/oropharyngeal swabs, and their limits of detection determined using viral plaque forming units (PFU). Three of the LFDs were selected for a further study, correlating antigen test result with RT-PCR Ct values and positive viral culture in Vero-E6 cells. This included sequential swabs and matched serum samples obtained from four infected individuals with varying disease severities. Detection of antibodies was performed using an IgG/IgM Rapid Test Cassette, and neutralising antibodies by infectious virus assay. Finally, the sensitivities of selected rapid antigen LFTs were assessed in swabs with confirmed B.1.1.7 variant, currently the dominant genotype in the UK. Findings: Most of the rapid antigen LFDs showed a high specificity (>98%), and accurately detected 50 PFU/test (equivalent N1 Ct of 23.7 or RNA copy number of 3x106/ml). Sensitivities of the LFDs performed on clinical samples ranged from 65 to 89%. These sensitivities increased in most tests to over 90% for samples with Cts lower than 25. Positive virus culture was achieved for 57 out of 141 samples, with 80% of the positive cultures from swabs with Cts lower than 23. Importantly, sensitivity of the LFDs increased to over 95% when compared with the detection of infectious virus alone, irrespective of Ct. Longitudinal studies of PCR-positive samples showed that most of the tests identified all infectious samples as positive, but differences in test sensitivities can lead to missed cases in the absence of repeated testing. Finally, test performance was not impacted when re-assessed against swabs positive for the dominant UK variant B.1.1.7. Interpretation: In this comprehensive comparison of antigen LFD and virus infectivity, we demonstrate a clear relationship between Ct values, quantitative culture of infectious virus and antigen LFD positivity in clinical samples. Our data support regular testing of target groups using LFDs to supplement the current PCR testing capacity, to rapidly identify infected individuals in situations where they would otherwise go undetected.

to economically and socially damaging restrictions to minimise the spread of SARS-CoV-2 71

and protect healthcare systems from being overwhelmed. 72 73

Pathways out of national lockdowns -and strategies to mitigate the need for them in the future 74 -depend upon the successful implementation of mass vaccination programmes, effective 75 contact tracing systems and mass community testing. In addition to the existing PCR-based 76 testing systems, the latter may take the form of targeted intensive testing in increasing 77 incidence areas, alongside regular routine screening in healthcare, education, workplace and 78 leisure settings. Realistically, the expansion of mass regular testing relies heavily on an element 79 of low-infrastructure-or self-testing, such as that offered by rapid antigen lateral flow devices 80 (LFDs). 1,2 81 82

Thoroughly understanding the advantages and limitations of rapid antigen LFDs is, therefore, 83 a priority and will help to inform decisions about where these tests will have the most utility 84 and, conversely, where they could be contraindicated. There are concerns about their reduced 85 sensitivity in comparison to PCR, and controversies have arisen over the suitability of their 86

implementation. [3] [4] [5] Problems with comparing Ct values from RT-qPCR between different 87 protocols, and even between the same protocols at different locations, combined with 88 uncertainty about the range of viral loads that constitute a transmission risk, have been the root 89 of many of the issues. 5,6 Individuals are most infectious around the time of symptom onset, 90 when viral loads in the upper respiratory tract are highest, 7,8 with recent studies confirming an 91 association between viral load and increased transmission of SARS-CoV-2. 9 For asymptomatic 92 individuals, infectivity and viral load dynamics involve a similar, limited, period of infectivity, 93 and asymptomatic and pre-symptomatic contributions to spread in the community remain 94 problematic. 10 Tests were performed according to the manufacturers' instructions, with the exception that 165 swabs stored in viral transport medium (VTM) were used for evaluations, rather than direct 166 swabs performed immediately prior to test performance. 50 ul of stored swab was mixed with 167 100 ul of buffer supplied with the test kit, and 100 ul of this was applied to the test cassette. 168

Results were scored at the time stipulated by the manufacturer (between 10 and 30 minutes). 169

Results were recorded independently by two readers, compared, and in the event of a discordant 170 score were referred to a third individual. For the purpose of comparison, chromatographic tests 171

were scored according to whether the test band was strongly positive (2), clearly positive (1), 172

weakly positive (0.5) or negative (0). 173 174 Funding sources had no involvement in the study design; in the collection, analysis, and 217 interpretation of the data; in the writing of the report; or in the decision to submit this 218 manuscript for publication. 219 220 221 222 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2021. ; https://doi.org/10.1101/2021.02.27.21252427 doi: medRxiv preprint

Head-to-head comparison of specificities, sensitivities and limits of detection of 225 commercial rapid antigen tests 226

Six commercial rapid antigen tests (Innova, E25 Bio, SureScreen visual (V), Spring, Encode 227

and SureScreen fluorescent (F); Table 1 ) were compared in specificity, limit-of-detection 228

(LOD) and sensitivity validations. 229 230

Comparative specificity was determined for each test using a panel of 100 SARS-CoV-2 231 negative swabs ( Figure 1A) . SureScreen V and Innova 246 had the lowest consistent LOD, and upon further testing SureScreen also consistently detected 247 20 PFU per test (600 PFU/mL; data not shown). Calibration experiments conducted on SARS-248

CoV-2 laboratory stocks ( Figure 1B ) and standardised RNA control reagents ( Figure 1C ) 249 delivered the equivalent N1 Ct of 23.7 or RNA copy number of 3x10 6 /ml for the LOD of 1500 250 PFU per mL. As particle-to-infectious unit ratios can vary between viral variants or according 251

to growth or assaying conditions, as an additional control we applied the Zeptometrix NATrol 252 inactivated viral particle standard to the two tests with the best LOD -Innova and SureScreen. 253

This was weakly positive on both tests at a copy number of 1.2x10 6 /ml (data not shown), or 254

projected Ct value of 25, in agreement with the results shown in Figure 1 .

Sensitivity comparisons on clinical samples were performed as head-to-head evaluations on 257 100 PCR-confirmed SARS-CoV-2 combined nasal/oropharyngeal swabs with Cts ranging 258 from 14 to 39 ( Figure 1D ). Swabs were selected to cover a wide range of Cts, from 14 to 39. 259

Overall sensitivities are presented, as well as sensitivities determined for samples with a Ct less 260 than 25, corresponding to approximately 1.5x10 6 copies/ml or 400 PFU/ml, and Ct 28, 261

corresponding to a copy number of approximately 1.65x10 5 copies/ml or 50 PFU/ml. Innova 262 had the highest overall sensitivity (89%) using clinical samples, with this increasing to 96 and 263 99% when applied to samples with Cts of less than 28 and 25 respectively ( Figure 2B) . Both viral culture and antigen test 283 positivity were associated with Ct value, rather than the timing of the sample post onset of 284 symptoms ( Figure 2C ).

Overall antigen test sensitivities and rankings were similar to those seen in Figure 1 , with 287

Innova delivering the highest sensitivity at 78%, then Encode (74%), followed by SureScreen 288 F (60%) ( Table 3) . When compared only to the samples from which virus was cultured, all 289

tests achieved a sensitivity of at least 95% (Figure 2A and SureScreen V, Innova and Encode), and positive viral culture ( Figure 2D) in one of these individuals. Longitudinal results therefore highlight the importance of repeat, 308 rather than one-off, testing with rapid antigen LFDs. 309 310

In two individuals, the occurrence of neutralising antibodies coincided with a dip in antigen 311 test band strength (Figure 2D ; patients 1 and 4). We also examined matched serum samples 312 from 76 of 141 samples shown in Figure 2A and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2021. ; https://doi.org/10.1101/2021.02.27.21252427 doi: medRxiv preprint compared to England 02/2020 (D3L, R203K, G204R and S235F). 16 We performed small-scale 322 evaluations using matched swab samples spanning a range of Cts (12.7 to 31.8), from April 323 2020, September 2020, and confirmed (by viral sequencing) B.1.1.7-positive swabs from 324 January 2021 (Figure 3) . Both Innova and SureScreen V tests showed variations in sensitivities 325 between the three batches of samples tested, as would be expected for biological samples, but 326

there was no evidence of altered sensitivity for the B.1.1.7 swabs. 327 328 329

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2021. In agreement with previous studies, we cultured virus from upper respiratory tract specimens 342

with Cts of up to 26 (an equivalent viral load of 7x10 5 copies/mL), 13,14,23 with the majority of 343 the culturable samples taken in the first week following symptom onset. 12-14, 24 The minimum 344 viral titre required for transmission is unclear 24 and will depend in part on the proximity and 345 duration of contact. Nevertheless, it has been reported that higher viral loads, as measured by 346

lower Ct, are strongly associated with transmission 9 and therefore reasonable to assume that 347 the quantity of cultured virus in vitro has a similar comparable correlation with infectivity. 348

There are, however, problems attempting to standardise Ct values as surrogate measures of 349 potential to transmit, due to differences in RNA extraction and RT-PCR methods. This is 350 demonstrated by a recent study in which differences of greater than 5 Cts between RT-PCR 351 systems prompted fears that rapid antigen LFDs were missing up to 50% of potentially 352 infectious cases. 4-6 There have been frequent suggestions for SARS-CoV-2 results to be 353

presented as viral load (copies/mL) due to difficulties in comparing Ct values between studies. 354

However, the lack of an agreed standard for determining viral load is itself a problem, with 355 reported viral loads often appearing even more disparate than Cts. 25 356 357

While the reduced sensitivity of LFDs relative to PCR is less of a concern late in the infection 358 course when Cts are rising and the risk of onward transmission is negligible, 9 it can be 359 problematic during the pre-symptomatic or early asymptomatic phase of infection. 10 As 360 demonstrated by our longitudinal studies (Figure 2D) Although the LFDs are very easy to use, the correct sampling, reading and interpretation of the 378 result are essential to their success in mass screening situations. 1 In particular, one must take 379 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2021. ; https://doi.org/10.1101/2021.02.27.21252427 doi: medRxiv preprint into account training and familiarity with swabbing when deploying devices to the general 380 public as compared with a trained healthcare worker in a hospital/clinic-based setting. It is 381 also easy to underestimate the importance of correctly recognising a positive band. We found 382 that some tests gave clearer results than other, as illustrated by the number of borderline results 383 seen in Figure 1 and 2. Removing this element of subjectivity, for example through the use of 384 an smartphone application to read/capture the LFD result, could improve success rates. 385 386

Our data support the judicious use of rapid antigen LFDs -not to replace PCR testing, but to 387 supplement the current testing capacity and rapidly identify infected individuals in situations 388

where they would otherwise go undetected. Although sensitivity is lower than PCR-based 389 testing, the rapid turnaround of these tests, their versatility in terms of cost and portability, and 390 their utility in disrupting transmission chains originating from infectious asymptomatic 391 individuals, outweighs the risk of missing positive cases. 392 393 394 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. presented as a heatmap; grey boxes indicate samples that were not tested on that particular test. 583

Sensitivity determinations from this sample set are shown to the right of the heatmap for each 584 test, showing overall sensitivity and sensitivity relative to infectious samples. 585 586 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 2, 2021. ; Table 2 : Comparative specificity and sensitivity of six commercial SARS-CoV-2 rapid antigen tests . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 2, 2021. ; https://doi.org/10.1101/2021.02.27.21252427 doi: medRxiv preprint Ct 28 300,000 30,000 6,000 3,000 1,500 300 30 PFU per mL . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 2, 2021. ; https://doi.org/10.1101/2021.02.27.21252427 doi: medRxiv preprint

Put to the test: use of rapid testing technologies for Covid-19

The effectiveness of population-wide, rapid 442 antigen based screening in reducing SARS-CoV-2 infection prevalence in Slovakia

Covid-19: government must urgently rethink lateral flow test 446 roll out

Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data show

Rapid coronavirus tests: a guide for the perplexed

Clarifying the evidence on 456 SARS-CoV-2 antigen rapid tests in public health responses to COVID-19

Temporal dynamics in viral shedding and transmissibility of 460 Covid-19

Duration of infectiousness and correlation with 463 RT-PCR cycle threshold values in cases of Covid-19

Transmission of Covid-19 in 282 clusters in 467

Spain: a cohort study

Clinical course and molecular viral shedding among 471 asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community 472 treatment center in the Republic of Korea

Virology, transmission, and pathogenesis of 475 SARS-CoV-2

Predicting infectious SARS-CoV-2 from diagnostic 478 samples

Duration of culturable SARS-CoV-2 in hospitalized 481 patients with Covid-19

Viral cultures for COVID-19 infectious 484 potential assessment -a systematic review

Longitudinal observation and decline of neutralizing 488 antibody responses in the three months following SARS-CoV-2 infection in humans. Nat 489 Microbiol

Genome sequence of a SARS-CoV-2 VUI 492 202012/01 strain identified from a patient returning from London, England, to the Apulia 493 region of Italy

The sensitivity of SARS-CoV-2 antigen tests in the 496 view of large-scale testing

Covid-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: a 499 national systemic evaluation for mass-testing

Comparison of seven commercial SARS-CoV-503 2 rapid point-of-care antigen tests

Evaluation of three rapid lateral flow antigen 507 detection tests for the diagnosis of SARS-CoV-2 infection

The comparative clinical performance of four SARS-511

CoV-2 rapid antigen tests and their correlation to infectivity in vitro

Point-of-CareTest Performance Compared to PCR-Based Testing and versus the Sofia 2 515 SARS Antigen Point-of-Care Test

Virological assessment of 518 hospitalized patients with Covid-19

SARS-CoV-2, SARS-CoV, 521 and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a 522 systematic review and meta-analysis. Lancet Microbe

RT-PCR for SARS-CoV-2: quantitative versus 526 qualitative

Real-world SARS-CoV-2 lateral flow antigen 529 detection device deployment in the emergency department to optimise safe, accurate and 530 rapid diagnosis of Covid-19

Long-term SARS-CoV-2 RNA shedding 533 and its temporal association to IgG seropositivity